Recursion Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75629V1044
SecurityMX:RXRX / Recursion Pharmaceuticals, Inc.
InstitutionJpmorgan Chase & Co
Latest Disclosed Ownership1,330,553 shares
Latest Disclosed Value $ 3,778,771
Jpmorgan Chase & Co reports 4.04% increase in ownership of RXRX / Recursion Pharmaceuticals, Inc.

On May 13, 2026 - Jpmorgan Chase & Co filed a 13F-HR/A form disclosing ownership of 1,330,553 shares of Recursion Pharmaceuticals, Inc. (MX:RXRX) valued at $3,778,771 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 1,278,944 shares of Recursion Pharmaceuticals, Inc.. This represents a change in shares of 4.04% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F/A-1 RECURSION PHARMACEUTICALS IN COMMON 75629V104 1,330,553 51,609 4.04 3,779 -27.76 0.0002
2026-02-11 2025-12-31 13F RECURSION PHARMACEUTICALS I COMMON 75629V104 1,278,944 859,326 204.79 5,231 155.50 0.0003
2025-11-26 2025-09-30 13F/A-1 RECURSION PHARMACEUTICALS IN COMMON 75629V104 419,618 20,115 5.04 2,048 1.29 0.0001
2025-11-07 2025-09-30 13F RECURSION PHARMACEUTICALS IN COMMON 75629V104 419,618 20,115 2,048 0.0001
2025-08-12 2025-06-30 13F RECURSION PHARMACEUTICALS IN COMMON 75629V104 399,503 -418,821 -51.18 2,021 -53.30 0.0001
2025-05-12 2025-03-31 13F RECURSION PHARMACEUTICALS IN COMMON 75629V104 818,324 -238,843 -22.59 4,329 -39.43 0.0003
2025-02-12 2024-12-31 13F RECURSION PHARMACEUTICALS IN COMMON 75629V104 1,057,167 -119,024 -10.12 7,146 -7.81 0.0005
2024-12-26 2024-09-30 13F/A-1 RECURSION PHARMACEUTICALS IN COMMON 75629V104 1,176,191 67,464 6.08 7,751 -6.78 0.0006
2024-11-08 2024-09-30 13F RECURSION PHARMACEUTICALS IN COMMON 75629V104 1,176,191 67,464 7,751 0.0006
2024-12-26 2024-06-30 13F/A-1 RECURSION PHARMACEUTICALS IN COMMON 75629V104 1,108,727 26,622 2.46 8,315 -22.92 0.0007
2024-08-12 2024-06-30 13F RECURSION PHARMACEUTICALS IN COMMON 75629V104 1,108,727 26,622 8,315 0.0007
2024-12-26 2024-03-31 13F/A-1 RECURSION PHARMACEUTICALS IN COMMON 75629V104 1,082,105 701,295 184.16 10,789 187.37 0.0009
2024-05-10 2024-03-31 13F RECURSION PHARMACEUTICALS IN COMMON 75629V104 1,082,105 701,295 10,789 0.0009
2024-12-26 2023-12-31 13F/A-1 RECURSION PHARMACEUTICALS IN COMMON 75629V104 380,810 -574,089 -60.12 3,755 -48.60 0.0004
2024-02-12 2023-12-31 13F RECURSION PHARMACEUTICALS IN COMMON 75629V104 380,810 -574,089 3,755 0.0004
2023-11-14 2023-09-30 13F RECURSION PHARMACEUTICALS IN COMMON 75629V104 954,899 580,038 154.73 7,305 160.86 0.0008
2023-08-11 2023-06-30 13F RECURSION PHARMACEUTICALS IN COMMON 75629V104 374,861 65,347 21.11 2,800 35.66 0.0003
2023-05-18 2023-03-31 13F/A-1 RECURSION PHARMACEUTICALS IN COMMON 75629V104 309,514 136,178 78.56 2,064 206,300.00 0.0003
2023-05-11 2023-03-31 13F RECURSION PHARMACEUTICALS IN COMMON 75629V104 204,825 31,489 2,064 0.0000
2023-02-13 2022-12-31 13F RECURSION PHARMACEUTICALS IN COMMON 75629V104 173,336 -7,802 -4.31 1 -99.95 0.0002
2022-11-14 2022-09-30 13F RECURSION PHARMACEUTICALS IN COMMON 75629V104 181,138 11,788 6.96 1,927 39.74 0.0003
2022-08-11 2022-06-30 13F RECURSION PHARMACEUTICALS IN COMMON 75629V104 169,350 42,311 33.31 1,379 51.54 0.0002
2022-05-11 2022-03-31 13F RECURSION PHARMACEUTICALS IN COMMON 75629V104 127,039 -29,390 -18.79 910 -66.03 0.0001
2022-02-11 2021-12-31 13F/A-1 RECURSION PHARMACEUTICALS IN COMMON 75629V104 156,429 124,826 394.98 2,679 268.50 0.0003
2022-02-10 2021-12-31 13F RECURSION PHARMACEUTICALS IN COMMON 75629V104 156,429 124,826 2,679 0.0003
2021-11-12 2021-09-30 13F RECURSION PHARMACEUTICALS IN COMMON 75629V104 31,603 11,611 58.08 727 -0.41 0.0001
2021-08-12 2021-06-30 13F RECURSION PHARMACEUTICALS IN COMMON 75629V104 19,992 19,992 730 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.